SC
ALLO icon

Samlyn Capital’s Allogene Therapeutics ALLO Stock Holding History

Samlyn Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-150,000
Closed -$4.04M – 99
2018
Q4 		$4.04M Buy
+150,000
New +$3.99M 0.1% 101

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Samlyn Capital's ALLO Position: Q1 2019 in Review

Samlyn Capital sold out of Allogene Therapeutics (ALLO) in Q1 2019, closing a stake of 150,000 shares — an estimated $4.04M sold.

Samlyn Capital first reported a position in ALLO in Q4 2018 and held it in 1 quarter. The position peaked at $4.04M in Q4 2018. 86 funds tracked by Wall St. Rank hold ALLO as of Q1 2019.

  • Samlyn Capital reported no remaining Allogene Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Samlyn Capital sold 150,000 Allogene Therapeutics shares in Q1 2019, an estimated $4.04M.
  • Samlyn Capital first reported a position in Allogene Therapeutics in Q4 2018 and held it in 1 quarter.
  • Samlyn Capital's Allogene Therapeutics position peaked at $4.04M in Q4 2018.
  • 86 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2019.

Based on Samlyn Capital's 13F filing for Q1 2019, filed 15 May 2019.